Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease



Status:Not yet recruiting
Conditions:Infectious Disease, Hepatitis
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:February 2016
End Date:May 2017

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

This study is evaluating the safety and efficacy of a 12 week treatment LDV/SOF FDC in
patients with Chronic GT1 or GT4 HCV infection and autoimmune disease


Inclusion Criteria:

- Chronic GT1 or GT4 HCV Infection

- Diagnosed with autoimmune disease (rheumatoid arthritis, psoriatic arthritis, lupus,
etc.) and is currently receiving treatment for the condition.

Exclusion Criteria:

- Infection with HIV or HBV
We found this trial at
1
site
Peter J. Ruane, MD, Inc.
Los Angeles, California 90036
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials